• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
El Ghandour, A., elhadidi, A., Ghallab, O., Nadwan, E., Eshra, R. (2022). PROTEIN ARGININE METHYLTRANSFERASE 1 EXPRESSION LEVEL AND ITS PROGNOSTIC SIGNIFICANCE IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS. ALEXMED ePosters, 4(3), 30-31. doi: 10.21608/alexpo.2022.160356.1463
Ashraf Hussein El Ghandour; abeer shawky elhadidi; Omar Mohamed Ghallab; Eman Attia Nadwan; Reem Abdelwahab Eshra. "PROTEIN ARGININE METHYLTRANSFERASE 1 EXPRESSION LEVEL AND ITS PROGNOSTIC SIGNIFICANCE IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS". ALEXMED ePosters, 4, 3, 2022, 30-31. doi: 10.21608/alexpo.2022.160356.1463
El Ghandour, A., elhadidi, A., Ghallab, O., Nadwan, E., Eshra, R. (2022). 'PROTEIN ARGININE METHYLTRANSFERASE 1 EXPRESSION LEVEL AND ITS PROGNOSTIC SIGNIFICANCE IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS', ALEXMED ePosters, 4(3), pp. 30-31. doi: 10.21608/alexpo.2022.160356.1463
El Ghandour, A., elhadidi, A., Ghallab, O., Nadwan, E., Eshra, R. PROTEIN ARGININE METHYLTRANSFERASE 1 EXPRESSION LEVEL AND ITS PROGNOSTIC SIGNIFICANCE IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS. ALEXMED ePosters, 2022; 4(3): 30-31. doi: 10.21608/alexpo.2022.160356.1463

PROTEIN ARGININE METHYLTRANSFERASE 1 EXPRESSION LEVEL AND ITS PROGNOSTIC SIGNIFICANCE IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS

Article 3, Volume 4, Issue 3, September 2022, Page 30-31  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2022.160356.1463
View on SCiNiTO View on SCiNiTO
Authors
Ashraf Hussein El Ghandour1; abeer shawky elhadidi2; Omar Mohamed Ghallab3; Eman Attia Nadwan1; Reem Abdelwahab Eshra email 4
1Department of Internal Medicine (Hematology Unit), Faculty of Medicine , Alexandria University
2department of chemical and clinical pathology, Faculty of medicine.
3department of internal medicine hematology unit
4Haematology Unit, Internal Medicine Department, Alexandria University, Egypt
Abstract
AML is a haematological malignancy characterized by a wide range of mutated genes and a wide genomic architecture composed of preleukemic and leukemic clones that unfold progressively over time. Protein arginine methylation is a posttranslational modification that is activated by the PRMT family of which PRMT1 is the most predominant isoform. PRMT1 was reported to be upregulated in breast cancer, lung cancer and colon cancer and to promote the proliferation and transformation of cancer cells. While the detailed function of PRMT1 in adult hematopoietic stem and progenitor cells (HSPCs) self-renewal and differentiation is still largely unknown, the role of PRMT1 in normal adult hematopoiesis has recently been identified.
Aim:
To evaluate the impact of the PRMT1 on response to induction chemotherapy in adult Egyptian AML patients.
Patients & Methods:
The presented study was conducted on 40 newly diagnosed AML patients in Alexandria University Main Hospital, Internal Medicine Department, Haematology Unit, from the period of December 2020 to August 2021. All of our patients were tested for PRMT1 gene expression level in bone marrow aspirate samples at time of initial diagnosis, as well as 20 healthy control subjects. Patients received standard [7+3] AML induction chemotherapy and follow up BMA assessment was done at day 28, assessing response to induction.
Keywords
PRMT1; ACUTE MYELOID LEUKEMIA; hematology
Supplementary Files
download 1463 19 (1).pdf
Statistics
Article View: 182
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.